Best Castleman Disease Hospitals in India

Fortis Hospital offers advanced Castleman Disease Treatment using modern diagnostic and therapeutic approaches and internationally accepted treatment protocols. Established in 2006, the JCI, NABH accredited hospital is located in Mohali, India, with 276 beds, providing comprehensive care for local and international patients.

Treatment depends on the type of Castleman disease, number of affected lymph node regions, symptoms, and associated conditions. Localised unicentric disease may often be treated with surgical removal of the affected lymph node, while multicentric disease may require medicines such as immunotherapy, corticosteroids, or other systemic treatments. Detailed evaluation helps determine the appropriate approach.

Fortis Hospital, Mulund offers specialised Castleman Disease Treatment using modern diagnostic technology and established haematology treatment protocols. Established in 2002, the JCI, NABH accredited hospital is situated in Mumbai, India, with 315 beds, serving local and international patients.

Treatment is personalised according to the disease subtype, extent, symptoms, and underlying cause. Surgery may be recommended for unicentric disease when the affected lymph node can be safely removed, while multicentric forms may require targeted immunotherapy or other systemic medicines. Before treatment, the multidisciplinary team conducts imaging, lymph-node evaluation, blood tests, and other investigations to develop an appropriate treatment plan.

At Manipal Hospital, Hebbal, patients can access comprehensive Castleman Disease Treatment supported by advanced diagnostic facilities and experienced specialists. Established in 1991, the NABL, NABH accredited hospital is located in Bangalore, India, and has 280 beds.

Castleman disease treatment is tailored according to whether the condition is unicentric or multicentric and whether an underlying infection or immune disorder is present. Surgery may be used for localised disease, while multicentric forms may require antibody-based therapy, corticosteroids, chemotherapy, or treatment of an associated condition. A thorough diagnostic assessment guides treatment selection.

Apollo Hospital International Limited provides Castleman Disease Treatment using contemporary haematology and immunotherapy approaches, along with evidence-based care. Founded in 2003, the NABH, JCI accredited hospital is based in Ahmedabad, India, with 300 beds and services for domestic and international patients.

The treatment approach depends on the subtype and severity of the disease. For unicentric Castleman disease, complete surgical removal may be sufficient in many cases. Multicentric disease may require systemic therapy, including medicines that target inflammatory pathways, corticosteroids, or other treatments based on the underlying cause and clinical presentation.

With advanced haematology and oncology infrastructure, Manipal Hospital, Gurugram offers Castleman Disease Treatment for patients requiring specialised management of this rare lymph-node disorder. Established in 2008, the NABL, NABH accredited hospital is located in Gurgaon, India, and has 380 beds.

For localised unicentric disease, treatment may involve surgical removal of the affected lymph node. Patients with multicentric disease may require systemic therapies, including anti-IL-6 therapy, other immunotherapies, corticosteroids, or chemotherapy in selected situations. Specialists assess lymph-node pathology, laboratory findings, symptoms, and associated infections or immune conditions before treatment.

Metro Hospital offers advanced Castleman Disease Treatment using modern diagnostic and therapeutic approaches and internationally accepted treatment protocols. Established in 1997, the NABL, NABH, ISO accredited hospital is located in Noida, India, with 289 beds, providing comprehensive care for local and international patients.

Treatment depends on the type of Castleman disease, number of affected lymph node regions, symptoms, and associated conditions. Localised unicentric disease may often be treated with surgical removal of the affected lymph node, while multicentric disease may require medicines such as immunotherapy, corticosteroids, or other systemic treatments. Detailed evaluation helps determine the appropriate approach.

With advanced haematology and oncology infrastructure, Medeor Hospital offers Castleman Disease Treatment for patients requiring specialised management of this rare lymph-node disorder. Established in 2007, the NABH, NABL accredited hospital is located in Delhi, India, and has 100 beds.

For localised unicentric disease, treatment may involve surgical removal of the affected lymph node. Patients with multicentric disease may require systemic therapies, including anti-IL-6 therapy, other immunotherapies, corticosteroids, or chemotherapy in selected situations. Specialists assess lymph-node pathology, laboratory findings, symptoms, and associated infections or immune conditions before treatment.

With advanced haematology and oncology infrastructure, Clear Medi Hospital, Karkardooma offers Castleman Disease Treatment for patients requiring specialised management of this rare lymph-node disorder. Established in 2017, the NABH, NABL accredited hospital is located in Delhi, India, and has 100 beds.

For localised unicentric disease, treatment may involve surgical removal of the affected lymph node. Patients with multicentric disease may require systemic therapies, including anti-IL-6 therapy, other immunotherapies, corticosteroids, or chemotherapy in selected situations. Specialists assess lymph-node pathology, laboratory findings, symptoms, and associated infections or immune conditions before treatment.

With advanced haematology and oncology infrastructure, American Oncology Institute offers Castleman Disease Treatment for patients requiring specialised management of this rare lymph-node disorder. Established in 2013, the NABH accredited hospital is located in Hyderabad, India, and has 150 beds.

For localised unicentric disease, treatment may involve surgical removal of the affected lymph node. Patients with multicentric disease may require systemic therapies, including anti-IL-6 therapy, other immunotherapies, corticosteroids, or chemotherapy in selected situations. Specialists assess lymph-node pathology, laboratory findings, symptoms, and associated infections or immune conditions before treatment.

With advanced haematology and oncology infrastructure, Bai Jerbai Wadia Hospital for Children offers Castleman Disease Treatment for patients requiring specialised management of this rare lymph-node disorder. Established in 1929, the AACI accredited hospital is located in Mumbai, India, and has 350 beds.

For localised unicentric disease, treatment may involve surgical removal of the affected lymph node. Patients with multicentric disease may require systemic therapies, including anti-IL-6 therapy, other immunotherapies, corticosteroids, or chemotherapy in selected situations. Specialists assess lymph-node pathology, laboratory findings, symptoms, and associated infections or immune conditions before treatment.

At Sanar International Hospital, patients can access comprehensive Castleman Disease Treatment supported by advanced diagnostic facilities and experienced specialists. Established in 2018, the NABH, JCI, AACI accredited hospital is located in Gurugram, India, and has 150 beds.

Castleman disease treatment is tailored according to whether the condition is unicentric or multicentric and whether an underlying infection or immune disorder is present. Surgery may be used for localised disease, while multicentric forms may require antibody-based therapy, corticosteroids, chemotherapy, or treatment of an associated condition. A thorough diagnostic assessment guides treatment selection.

At The Medical Park, patients can access comprehensive Castleman Disease Treatment supported by advanced diagnostic facilities and experienced specialists. Established in 1987, the accredited hospital is located in Chennai, India, and has 300 beds.

Castleman disease treatment is tailored according to whether the condition is unicentric or multicentric and whether an underlying infection or immune disorder is present. Surgery may be used for localised disease, while multicentric forms may require antibody-based therapy, corticosteroids, chemotherapy, or treatment of an associated condition. A thorough diagnostic assessment guides treatment selection.

With advanced haematology and oncology infrastructure, Apollo Multispecialty Hospitals offers Castleman Disease Treatment for patients requiring specialised management of this rare lymph-node disorder. Established in 2003, the JCI, ISO accredited hospital is located in Kolkata, India, and has 700 beds.

For localised unicentric disease, treatment may involve surgical removal of the affected lymph node. Patients with multicentric disease may require systemic therapies, including anti-IL-6 therapy, other immunotherapies, corticosteroids, or chemotherapy in selected situations. Specialists assess lymph-node pathology, laboratory findings, symptoms, and associated infections or immune conditions before treatment.

Apollo Hospital offers advanced Castleman Disease Treatment using modern diagnostic and therapeutic approaches and internationally accepted treatment protocols. Established in 1983, the JCI accredited hospital is located in Chennai, India, with 550 beds, providing comprehensive care for local and international patients.

Treatment depends on the type of Castleman disease, number of affected lymph node regions, symptoms, and associated conditions. Localised unicentric disease may often be treated with surgical removal of the affected lymph node, while multicentric disease may require medicines such as immunotherapy, corticosteroids, or other systemic treatments. Detailed evaluation helps determine the appropriate approach.

Fortis Hospital provides Castleman Disease Treatment using contemporary haematology and immunotherapy approaches, along with evidence-based care. Founded in 2004, the NABH, NABL accredited hospital is based in Noida, India, with 400 beds and services for domestic and international patients.

The treatment approach depends on the subtype and severity of the disease. For unicentric Castleman disease, complete surgical removal may be sufficient in many cases. Multicentric disease may require systemic therapy, including medicines that target inflammatory pathways, corticosteroids, or other treatments based on the underlying cause and clinical presentation.